Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DILEEP PUPPALA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1215989900
CMS profile
282497
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$17,360.76

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DILEEP PUPPALA

NPI 1215989900 · CMS profile ID 282497

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DILEEP PUPPALA, NPI 1215989900, CMS profile ID 282497, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1215989900?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $17,360.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Octapharma USA, Inc. $33.3109/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812975693 CMS
Optinose US, Inc. $23.8409/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851673217 CMS
GlaxoSmithKline, LLC. $4.8209/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802254835 CMS
GlaxoSmithKline, LLC. $13.5708/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802504873 CMS
Chiesi USA, Inc. $15.9808/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849057363 CMS
Actelion Pharmaceuticals US, Inc. $22.9308/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002823 CMS
GlaxoSmithKline, LLC. $1,800.0008/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803101653 CMS
AbbVie Inc. $15.8908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795722567 CMS
Regeneron Healthcare Solutions, Inc. $992.0008/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809615433 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.1908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763465126 CMS
GENZYME CORPORATION $17.5108/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843550189 CMS
JAZZ PHARMACEUTICALS INC. $12.4608/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845617443 CMS
Regeneron Healthcare Solutions, Inc. $17.3308/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809615431 CMS
GlaxoSmithKline, LLC. $14.8408/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803107471 CMS
Janssen Pharmaceuticals, Inc $14.0808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002813 CMS
Chiesi USA, Inc. $17.3108/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849050435 CMS
JAZZ PHARMACEUTICALS INC. $10.6508/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845617441 CMS
GlaxoSmithKline, LLC. $3.2307/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802791687 CMS
HARMONY BIOSCIENCES LLC $21.4907/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853086049 CMS
JAZZ PHARMACEUTICALS INC. $22.8807/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845617439 CMS
AstraZeneca Pharmaceuticals LP $18.2207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834329091 CMS
AstraZeneca Pharmaceuticals LP $23.2407/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834354265 CMS
Grifols USA, LLC $12.3407/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846764961 CMS
JAZZ PHARMACEUTICALS INC. $18.3807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845617445 CMS
AstraZeneca Pharmaceuticals LP $17.2007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834348963 CMS
Insmed, Inc. $23.5507/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851726417 CMS
HARMONY BIOSCIENCES LLC $12.3307/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853086041 CMS
Mallinckrodt Hospital Products Inc. $12.1307/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845375011 CMS
Mallinckrodt Hospital Products Inc. $31.4907/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845375009 CMS
Actelion Pharmaceuticals US, Inc. $28.6007/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002841 CMS
United Therapeutics Corporation $21.8807/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839133025 CMS
United Therapeutics Corporation $21.8807/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839133027 CMS
GENZYME CORPORATION $17.2507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843550187 CMS
Janssen Pharmaceuticals, Inc $17.3007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002815 CMS
GlaxoSmithKline, LLC. $3,600.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802017853 CMS
Regeneron Healthcare Solutions, Inc. $17.6307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809615429 CMS
HARMONY BIOSCIENCES LLC $23.2906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853086039 CMS
United Therapeutics Corporation $107.6906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839136487 CMS
Regeneron Healthcare Solutions, Inc. $100.3206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809615427 CMS
Actelion Pharmaceuticals US, Inc. $23.0906/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002837 CMS
JAZZ PHARMACEUTICALS INC. $22.3206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845629517 CMS
HARMONY BIOSCIENCES LLC $8.3306/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853086047 CMS
JAZZ PHARMACEUTICALS INC. $19.6106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845627617 CMS
JAZZ PHARMACEUTICALS INC. $15.5306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845627615 CMS
Janssen Pharmaceuticals, Inc $13.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788002817 CMS
GlaxoSmithKline, LLC. $10.9306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802954499 CMS
Insmed, Inc. $26.8206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851726419 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $13.3906/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815011531 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $17.1606/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815011538 CMS
E.R. Squibb & Sons, L.L.C. $13.5205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783534685 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $35,071.11 198
PY2020 $31,146.69 144
PY2021 $17,360.76 155
PY2022 $10,077.13 161
PY2023 $5,053.38 180
PY2024 $3,088.76 124
PY2025 $5,738.23 178

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $462,347.37 124
PY2024 Principal investigator $89,210.51 36
PY2023 Principal investigator $147,626.44 41
PY2022 Principal investigator $141,893.82 36
PY2021 Principal investigator $67,525.35 23
PY2020 Principal investigator $36,442.35 3
PY2019 Principal investigator $47,535.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $2,737.50 12/17/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680760
Principal investigator 1 Boehringer Ingelheim International GmbH $127.60 12/17/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680762
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 12/17/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680764
Principal investigator 1 GlaxoSmithKline, LLC. $3,577.81 12/11/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192144299
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680740
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680742
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680744
Principal investigator 1 GlaxoSmithKline, LLC. $19,593.09 11/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192183591
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680756
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 11/19/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680758
Principal investigator 1 GlaxoSmithKline, LLC. $1,087.78 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183566
Principal investigator 1 GlaxoSmithKline, LLC. $2,740.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183575
Principal investigator 1 GlaxoSmithKline, LLC. $3,356.50 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183586
Principal investigator 1 GlaxoSmithKline, LLC. $1,712.50 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183599
Principal investigator 1 Verona Pharma, Inc. $647.33 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891783
Principal investigator 1 Verona Pharma, Inc. $1,065.15 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891785
Principal investigator 1 Verona Pharma, Inc. $990.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891787
Principal investigator 1 Verona Pharma, Inc. $16,605.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891789
Principal investigator 1 Verona Pharma, Inc. $900.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891791
Principal investigator 1 Verona Pharma, Inc. $10,935.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891793
Principal investigator 1 Verona Pharma, Inc. $540.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891795
Principal investigator 1 Verona Pharma, Inc. $3,105.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891797
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 11/17/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220814537
Principal investigator 1 Verona Pharma, Inc. $62,586.68 11/14/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891751
Principal investigator 1 Verona Pharma, Inc. $1,120.00 11/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891821
Principal investigator 1 Verona Pharma, Inc. $6,090.00 11/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891823
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680734
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680736
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680738
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 10/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680746
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 10/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680748
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 10/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680750
Principal investigator 1 Boehringer Ingelheim International GmbH $4.65 10/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680752
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 10/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680754
Principal investigator 1 GlaxoSmithKline, LLC. $4,841.99 10/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183548
Principal investigator 1 PFIZER INC. $143.30 10/24/2025 Non-covered Recipient Entity
HOUSTON PULMONARY SLEEP AND ALLERGY ASSOCIATESDBA TEXAS MULTISPECIALTY GROUP
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228823550
Principal investigator 1 GlaxoSmithKline, LLC. $4,767.84 10/23/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099776
Principal investigator 1 Verona Pharma, Inc. $45,555.05 10/10/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891749
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/08/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192181982
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 10/06/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680718
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 10/06/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680720
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 10/06/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680722
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 10/06/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680724
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 10/06/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680726
Principal investigator 1 GlaxoSmithKline, LLC. $2,790.00 10/02/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144288
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680728
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680730
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680732
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 09/24/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680710
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 09/24/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680712
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 09/24/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680714
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 09/24/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680716
Principal investigator 1 GlaxoSmithKline, LLC. $10,899.90 09/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192183553
Principal investigator 1 GlaxoSmithKline, LLC. $3,577.81 09/18/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192183561
Principal investigator 1 GlaxoSmithKline, LLC. $16,757.84 09/17/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192099750
Principal investigator 1 GlaxoSmithKline, LLC. $2,065.96 09/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192181986
Principal investigator 1 GlaxoSmithKline, LLC. $8,436.46 09/10/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192181999
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680766
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680768
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680770
Principal investigator 1 PFIZER INC. $2,181.60 09/07/2025 Non-covered Recipient Entity
HOUSTON PULMONARY SLEEP AND ALLERGY
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228823529
Principal investigator 1 GlaxoSmithKline, LLC. $16,301.36 09/03/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192133291
Principal investigator 1 GlaxoSmithKline, LLC. $3,736.26 09/03/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192183578
Principal investigator 1 Verona Pharma, Inc. $16,500.00 09/03/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891667
Principal investigator 1 Verona Pharma, Inc. $1,852.00 09/03/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROU
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891669
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680696
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680698
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680700
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 08/26/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680702
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680704
Principal investigator 1 Boehringer Ingelheim International GmbH $9.30 08/26/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680706
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 08/26/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680708
Principal investigator 1 GlaxoSmithKline, LLC. $22,092.84 08/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192181990
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,250.00 08/12/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220814535
Principal investigator 1 GlaxoSmithKline, LLC. $7,485.39 08/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192181974
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680690
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680692
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680694
Principal investigator 1 GlaxoSmithKline, LLC. $3,973.00 08/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192133256
Principal investigator 1 GlaxoSmithKline, LLC. $27,640.00 08/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192133270
Principal investigator 1 GlaxoSmithKline, LLC. $978.18 07/25/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192099757
Principal investigator 1 GlaxoSmithKline, LLC. $1,485.00 07/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192133264
Principal investigator 1 GlaxoSmithKline, LLC. $3,037.50 07/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192133285
Principal investigator 1 GlaxoSmithKline, LLC. $4,050.00 07/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192144295
Principal investigator 1 GlaxoSmithKline, LLC. $4,383.72 07/18/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192181994
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680684
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680686
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680688
Principal investigator 1 GlaxoSmithKline, LLC. $3,396.17 06/20/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192099745
Principal investigator 1 GlaxoSmithKline, LLC. $81.38 06/20/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192144283
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192183571
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680660
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680662
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680664
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680666
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680668
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680670
Principal investigator 1 Boehringer Ingelheim International GmbH $186.56 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680672
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680674
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680676
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680678
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680680
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/27/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680682
Principal investigator 1 GlaxoSmithKline, LLC. $2,828.00 05/09/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144303
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 05/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680654
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 05/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680656
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 05/01/2025 Non-covered Recipient Entity
Houston Pulmonary Sleep And Allergy Associates
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220680658
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 04/28/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183539
Principal investigator 1 GlaxoSmithKline, LLC. $15,158.56 04/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192099764
Principal investigator 1 GlaxoSmithKline, LLC. $1,449.00 04/16/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192183557
Principal investigator 1 GlaxoSmithKline, LLC. $10,642.89 04/09/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192099769
Principal investigator 1 GlaxoSmithKline, LLC. $3,425.00 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192133243
Principal investigator 1 GlaxoSmithKline, LLC. $2,397.50 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192133251
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192133279
Principal investigator 1 GlaxoSmithKline, LLC. $1,712.50 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192144291
Principal investigator 1 GlaxoSmithKline, LLC. $5,007.46 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192181970
Principal investigator 1 GlaxoSmithKline, LLC. $2,493.40 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192181979
Principal investigator 1 GlaxoSmithKline, LLC. $4,693.62 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183535
Principal investigator 1 GlaxoSmithKline, LLC. $3,973.00 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183582
Principal investigator 1 GlaxoSmithKline, LLC. $17,570.25 03/21/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183595
Principal investigator 1 GlaxoSmithKline, LLC. $3,537.23 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192099784
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,850.00 01/29/2025 Non-covered Recipient Entity
ACE CLINICAL RESEARCH GROUP
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185550757
Principal investigator 1 GlaxoSmithKline, LLC. $3,971.25 01/09/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192183543
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,486.59 01/08/2025 Non-covered Recipient Entity
ACE CLINICAL RESEARCH GROUP
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185550759